Antibodies: Timeline of key events

Mouseover the event title for a more detailed description of the event (if available). To search for particular terms in the description of the event enter the term in the box below 'Event' on the table and press 'enter'. Alternatively use the dropdown lists to filter by Person, Place or Science. Click here to clear the filter.

Abciximab (ReoPro) approved by the FDA and European regulatory authorities to prevent blot clots during coronary artery procedures like angioplasty. The monoclonal antibody was originally developed by Barry Coller at State University of New York and commercially developed by Centocor. The drug showed for the first time that monoclonal antibodies could be used for the treatment of acute disease conditions. 1994-12-01T00:00:00+0000German regulatory authorities approve Panorex as an adjuvant therapy, that is a drug given in addition to primary or main treatment, for postoperative colorectal cancer. The drug originated from resesearch undertaken by Hilary Koprowski and his colleagues at the Wistar Institute. 1995-01-01T00:00:00+0000German regulatory authorities approve edrecolomab (Panorex) as an adjuvant treatment for post-operative colorectal cancer. The monoclonal antibody, originally known as 17-1A, was developed at the Wistar Institute and commercially developed for market by Centocor. 1995-01-01T00:00:00+0000Kohler co-pioneered the first monoclonal antibodies which today are a major component in diagnostics and blockbuster drugs.1995-03-01T00:00:00+0000Ritxuan (rituiximab) is approved for the treatment of non-Hodgkin Lymphoma. The drug arose out of Ronald Levy's research for three decades to find a way of harnessing the power of the body's own immune system to fight cancer. 1997-01-01T00:00:00+0000Daclizumab was approved by the FDA for the preventition of acute rejection of kidney transplants. The monoclonal antibody was developed by Protein Design Labs using a humanising method devised by Cary Queen and marketed together with F. Hoffmann-La Roche. 1997-12-01T00:00:00+0000The drug is a monoclonal antibody that targets cancer cells that overproduce the HER2/neu oncoprotein1998-01-01T00:00:00+0000Remicade (infliximab) is approved for the treatment of Crohn's disease. Soon after Remicade wins approval for other autoimmune and inflammatory conditions including rheumatoid arthritis and ulcerative colitis. The drug, a monoclonal antibody against TNF alpha, a powerful promoter of inflammation, was developed in 1989 by Jan Vilcek and Jumning Le and developed in collaboration with Centocor, Marc Feldmann and Maini1998-08-01T00:00:00+0000Launched by the biotechnology company Medarex in collaboration with Jim Allison. 2000-01-01T00:00:00+0000A Canadian biochemist, Michael Smith helped develop site-direct mutagenesis, a technique that allows for a mutation to be created at a specific defined site in a DNA molecule. This technique is pivotal to genetic and protein research and engineering. 2000-10-04T00:00:00+0000Adalimumab (Humira) approved by the FDA for the treatment of rheumatoid arthritis. The drug was developed and marketed by a collaboration between Cambridge Antibogy Technology, BASF Bioresearch Corporation and Abbott Laboratories.2002-12-31T00:00:00+0000The diagnostic, called NeutroSpectT, uses a monoclonal antibody, SSEA1, discovered at the Wistar Institute and developed by Palatin Technologies.2004-04-05T00:00:00+0000The two companies agreed to share the costs and responsibilities of research and product development up to the completion of a Phase 2 clinical study in each party's territory.2005-05-01T00:00:00+0000Panitumumab (Vectibix) was approved by the FDA for the treatment of patients with EGFR-expressing metatastic colorectal cancer. The drug is a fully human monoclonal antibody created with transgenic mice. It was developed by Agensys with Amgen. 2006-09-27T00:00:00+0000Drug, MSX-1106, to be assessed for malignant melanoma, renal cell cancer, castrate-resistant prostate cancer and non-small cell lung carcinoma2008-11-24T00:00:00+0000The drug was approved for the treatment of unresectable or metastatic melanoma. The drug uses a monoclonal that blocks CTLA-4 so as to activate an immune response against the cancer.2011-03-25T00:00:00+0000Edelman shared the 1972 Nobel Prize for Medicine for discoveries concerning the chemical structure of antibodies. 2014-05-17T00:00:00+0000The drug was developed by scientists at Medarex2014-09-01T00:00:00+0000The drug, a monoclonal antibody, was approved by the FDA for the treatment of patients with melanoma. 2014-12-22T00:00:00+0000Results presented to American Society for Clinical Conference from trials involving monoclonal antibody drugs for lung and skin cancer. The drugs block a protein known as PD-1, which functions as an immune checkpoint, being responsible for preventing the activation of T-cells.2015-06-05T00:00:00+0000
Date Event People Places Sciences
1994First chimeric monoclonal antibody therapeutic approved for marketCollerCentocor, State University of New YorkMonoclonal antibodies, Recombinant DNA
1995First monoclonal antibody drug for cancer approved in EuropeKoprowski Monoclonal antibodies
1995First monoclonal antibody therapeutic for cancer approved for marketKoprowskiWistar Institute, CentocorMonoclonal antibodies
1 Mar 1995Georges Kohler diedKohlerLaboratory of Molecular BiologyMonoclonal antibodies
1997FDA approved the first monoclonal antibody cancer drug for the American marketLevy, RastetterStanford University Medical School, Idec PharmaceuticalsCancer immunotherapy, Monoclonal antibodies
Dec 1997First humanised monoclonal antibody approved for marketQueenProtein Design Labs, RocheMonoclonal antibodies, Recombinant DNA
1998FDA approved Trastuzumab (Herceptin) for the treatment of metastatic breast cancer   Monoclonal antibodies, Oncology
Aug 1998FDA and European regulatory authorities approved the first monoclonal antibody drug for an autoimmune diseaseVilcek, Le, Feldmann, MainiNew York University, Centocor, Kennedy Institute of RheumatologyMonoclonal antibodies
2000First clinical trials launched to test first immune checkpoint inhibitor drug containing a monoclonal antibody against CTLA-4 (ipilimumab, Yervoy®)AllisonMedarex, University of California BerkleyImmune checkpoint inhibitors, Immunology, Cancer immunotherapy, Oncology, Monoclonal antibodies
4 Oct 2000Michael Smith died University of British ColumbiaRecombinant DNA, Monoclonal antibodies
Dec 2002First monoclonal antibody made using phage display approved for market CAT, BASF, AbbottMonoclonal antibodies, Phage display
Apr 2004US FDA approved new imaging agent for detecting difficult to diagnose cases of appendicitis Wistar Institute, Palatin TechnologiesMonoclonal antibodies
May 2005Medarex and Ono Pharmaceuticals entered research alliance to develop a fully human anti-PD-1 antibody for the treatment of cancer Medarex, Ono PharmaceuticalImmune checkpoint inhibitors, Immunotherapy, Monoclonal antibodies
Sep 2006First fully human monoclonal antibody drug approved Agensys, AmgenMonoclonal antibodies, transgenic
24 Nov 2008First anti-PD-1 antibody entered phase 1 clinical trial for cancer Medarex, Ono PharmaceuticalImmune checkpoint inhibitors, Immunotherapy, Monoclonal antibodies
25 Mar 2011First immune checkpoint inhibitor drug targeting CTLA4 (ipilimumab, Yervoy®), approved by the FDAAllisonMedarex, University of California BerkleyImmune checkpoint inhibitors, Cancer immunotherapy, Oncology, Monoclonal antibodies
17 May 2014Gerald M Edelman diedEdelmanRockefeller UniversityAntibodies
Sep 2014FDA approved nivolumab (Opdivo®), an immune checkpoint inhibitor targeting PD1, for treating melanoma  Immune checkpoint inhibitors, Immuotherapy, Oncology, Monoclonal antibodies
22 Dec 2014First immune checkpoint inhibitor drug targeting PD-1 (nivolumab, Opdivo®) approved in US Honko, Freeman, LonbergMedarex, Bristol-Myers Squibb, Ono PharmaceuticalImmune checkpoint inhibitors, Cancer immunotherapy, Oncology, Monoclonal antibodies
5 Jun 2015Two immunotherapy drugs reported to stop cancer cells avoiding destruction by immune system   Cancer immunotherapy, Oncology, Monoclonal antibodies

1994

First chimeric monoclonal antibody therapeutic approved for market

1995

First monoclonal antibody drug for cancer approved in Europe

1995

First monoclonal antibody therapeutic for cancer approved for market

1 Mar 1995

Georges Kohler died

1997

FDA approved the first monoclonal antibody cancer drug for the American market

Dec 1997

First humanised monoclonal antibody approved for market

1998

FDA approved Trastuzumab (Herceptin) for the treatment of metastatic breast cancer

Aug 1998

FDA and European regulatory authorities approved the first monoclonal antibody drug for an autoimmune disease

2000

First clinical trials launched to test first immune checkpoint inhibitor drug containing a monoclonal antibody against CTLA-4 (ipilimumab, Yervoy®)

4 Oct 2000

Michael Smith died

Dec 2002

First monoclonal antibody made using phage display approved for market

Apr 2004

US FDA approved new imaging agent for detecting difficult to diagnose cases of appendicitis

May 2005

Medarex and Ono Pharmaceuticals entered research alliance to develop a fully human anti-PD-1 antibody for the treatment of cancer

Sep 2006

First fully human monoclonal antibody drug approved

24 Nov 2008

First anti-PD-1 antibody entered phase 1 clinical trial for cancer

25 Mar 2011

First immune checkpoint inhibitor drug targeting CTLA4 (ipilimumab, Yervoy®), approved by the FDA

17 May 2014

Gerald M Edelman died

Sep 2014

FDA approved nivolumab (Opdivo®), an immune checkpoint inhibitor targeting PD1, for treating melanoma

22 Dec 2014

First immune checkpoint inhibitor drug targeting PD-1 (nivolumab, Opdivo®) approved in US

5 Jun 2015

Two immunotherapy drugs reported to stop cancer cells avoiding destruction by immune system